- Home
- UGRO vs BCAB Comparison
UGRO vs BCAB Comparison
Compare UGRO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UGRO | BCAB |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | 61 |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 11.2M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UGRO | BCAB |
|---|---|---|
| Price | $19.23 | $0.13 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 10.3M | 1.0M |
| Earning Date | 02-17-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,008,850.00 | $300,000.00 |
| Revenue This Year | $98.41 | N/A |
| Revenue Next Year | $23.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $0.12 |
| 52 Week High | $39.68 | $1.43 |
Technical Indicators
Market Signals| Indicator | UGRO | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 62.32 | 36.29 |
| Support Level | $0.71 | N/A |
| Resistance Level | $39.68 | $0.21 |
| Average True Range (ATR) | 6.81 | 0.02 |
| MACD | 1.29 | 0.00 |
| Stochastic Oscillator | 45.51 | 11.76 |
Price Performance
Historical ComparisonAbout UGRO urban-gro Inc.
Urban-gro Inc operated as an integrated professional services and design-build firm offering architectural, engineering, and construction management solutions to the CEA, industrial, healthcare, and other commercial sectors. The company generated revenue by billing employees time on client projects and provided architectural, engineering, systems procurement and integration, and construction design-build solutions with a single point of accountability. For CEA clients, it developed indoor cultivation facilities for specialty crops, including cannabis and produce such as leafy greens, vegetables, herbs, and berries. Its segments included Equipment Systems (commercial horticulture equipment), Services (design-build services), and Construction Design-Build (general contracting).
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.